RheumaGen
RheumaGen is a private biotechnology company dedicated to engineering a new class of therapeutics to cure major autoimmune diseases at their source. Focused on editing the human leukocyte antigen (HLA), or 'immune gene,' RheumaGen develops one-time, curative cell and gene therapies. Their mission is to make possible for patients what no one thought could be achieved through editing the HLA, transforming autoimmunity and seeking cures and remission for autoimmune diseases.
Industries
Nr. of Employees
small (1-50)
RheumaGen
Bioscience 1, 12635 E Montview Blvd., Suite 137, Aurora, CO 80045
Products
RG0401
A lead HLA gene-edited autologous hematopoietic stem cell therapy program in development for treatment-resistant or refractory rheumatoid arthritis; undergoing IND-enabling studies with Phase I clinical trial planned.
RG0401
A lead HLA gene-edited autologous hematopoietic stem cell therapy program in development for treatment-resistant or refractory rheumatoid arthritis; undergoing IND-enabling studies with Phase I clinical trial planned.
Services
Collaboration with a university-affiliated clinical laboratory to leverage FDA-licensed facilities and stem-cell processing accreditation for manufacturing and process development of cell and gene therapies.
Execution of IND-enabling preclinical studies and preparation of regulatory documentation to support early-phase clinical development for HLA gene-edited therapies.
Collaboration with a university-affiliated clinical laboratory to leverage FDA-licensed facilities and stem-cell processing accreditation for manufacturing and process development of cell and gene therapies.
Execution of IND-enabling preclinical studies and preparation of regulatory documentation to support early-phase clinical development for HLA gene-edited therapies.
Expertise Areas
- HLA-focused immunogenetics
- Cell and gene therapy (CGT) development
- Autologous hematopoietic stem cell therapies
- IND-enabling nonclinical studies and regulatory strategy
Key Technologies
- HLA gene editing
- RNA-guided genome editing
- Ex vivo hematopoietic stem cell editing
- Autologous stem cell infusion
News & Updates
RheumaGen CEO Richard Freed was invited to speak on the “Transformative Innovations in Colorado Advancing Regenerative Medicine” panel at the 2024 Biotech Symposium: Innovations in Regenerative Medicine on Tuesday, April 23, 2024. Freed highlighted the shifting landscape in regenerative medicine, saying, “We can use words like ‘cures’ now. We can see the future, and it’s really exciting for all of us.”
May 29, 2025 - RheumaGen is developing a breakthrough class of cell and gene therapies designed to cure autoimmune diseases at their source, focusing on editing the human leukocyte antigen (HLA).
RheumaGen was awarded the top prize at the Colorado BioScience Association’s Innovation Showcase for its innovative approach to HLA gene editing to treat autoimmune diseases.
RheumaGen CEO Richard Freed was invited to speak on the “Transformative Innovations in Colorado Advancing Regenerative Medicine” panel at the 2024 Biotech Symposium: Innovations in Regenerative Medicine on Tuesday, April 23, 2024. Freed highlighted the shifting landscape in regenerative medicine, saying, “We can use words like ‘cures’ now. We can see the future, and it’s really exciting for all of us.”
May 29, 2025 - RheumaGen is developing a breakthrough class of cell and gene therapies designed to cure autoimmune diseases at their source, focusing on editing the human leukocyte antigen (HLA).
RheumaGen was awarded the top prize at the Colorado BioScience Association’s Innovation Showcase for its innovative approach to HLA gene editing to treat autoimmune diseases.